Biotech Takeover Favourite Abivax Loses Over 30% as Trial Safety Concerns Eclipse Strong Drug Results
Abivax, which has spent the past year at the centre of intense takeover speculation, announced that its experimental ulcerative colitis treatment, obefazimod, successfully met both primary and key secondary endpoints in…